A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.

The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.

The results of this study were published in the prestigious New England Journal of Medicine.

To read the article in Le Devoir, click here.